Potential markers for early diagnostics of Colorectal cancer and Inflammatory bowel disease in humans : intestinal microorganisms and immune system (teammates or rivals)

Authors Affiliation(s)

  • 1Department of Surgery, 1st Medical Faculty, Charles University and Hospital Na Bulovce, Prague, CZECH REPUBLIC
  • 2Laboratory of Tumour Biology, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, v.v.i., Libechov, CZECH REPUBLIC

Can J Biotech, Volume 1Issue 2,  Pages 59-64,  DOI: https://doi.org/10.24870/cjb.2017-000109

Received: Apr 28, 2017; Revised: May 30, 2017; Accepted: Jun 7, 2017

Abstract

Chronic inflammation of the bowel is the characteristic of Inflammatory bowel diseases including Ulcerative colitis and Crohn’s disease. The incidence of Inflammatory bowel disease (IBD) in Western Europe is 14/100,000 of inhabitants. Duration and severity of inflammation increases the risk of Colorectal cancer (CRC) development by about 60% in IBD patients. CRC is the 3rd most common type of tumor in Western population. Every year, more than one million new cases are diagnosed with more than 600,000 deaths.

The early detection of CRC, originating from any part of the colon-rectum, is desirable because it can be cured surgically if diagnosed timely. Identification of new early markers for IBD and CRC is very important.

This review deals with the searching and identification of possibly new early markers for the above mentioned pathologies. We have focused on intestinal microorganisms (changes in qualitative and quantitative composition of microbiome, selection of candidate microorganisms) and immune system markers (cytokines, chemokines, nuclear factor kB, Toll-like receptors and Receptor for Advanced Glycation End Products).

References

  1. Franke, A., McGovern, D.P., Barrett, J.C., Wang, K., Radford-Smith, G.L., Ahmad T. et al. (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42: 1118-1125. Crossref
  2. Franke, A., Hampe, J., Rosenstiel, P., Becker, C., Wagner, F., Häsler, R. et al. (2007) Systematic association mapping identifies NELL1 as a novel IBD disease gene.  PLoS One 2: e691. Crossref
  3. Satsangi, J., Silverberg, M.S., Vermeire, S. and Colombel, J.F. (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.  Gut 55: 749-753. Crossref
  4. Vegh, Z., Burisch, J., Pedersen, N., Kaimakliotis, I., Duricova, D., Bortlik, M. et al. (2014). Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort.  J Crohns Colitis 8: 1506-1515. Crossref
  5. Allen-Vercoe, E. and Jobin, C. (2014) Fusobacterium and Enterobacteriaceae: Important players for CRC?  Immunol Lett 162: 54-61. Crossref
  6. Abi-Habib, R.J., Singh, R., Liu, S., Bugge, T.H., Leppla, S.H. and Frankel, A.E. (2006) A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.  Mol Cancer Ther 5: 2556-2562. Crossref
  7. Candela, M., Turroni, S., Biagi, E., Carbonero, F., Rampelli, S., Fiorentini, C. and Brigidi, P. (2014) Inflammation and colorectal cancer, when microbiota-host mutualism breaks.  World J Gastroenterol 20: 908-922. Crossref
  8. Bonnet, M., Buc, E., Sauvanet, P., Darcha, C., Dubois, D., Pereira, B., Déchelotte, P., Bonnet, R., Pezet, D. and Darfeuille-Michaud, A. (2014) Colonization of the human gut by E. coli and colorectal cancer risk.  Clin Cancer Res 20: 859-867. Crossref
  9. Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S. and Zhao, L. (2012) Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers.  ISME J 6: 320-329. Crossref
  10. Fric, P. (2002) Screening programs for sporadic colorectal carcinoma.  Vnitr Lek 48: 556-559.
  11. Liu, Z., Cao, A.T. and Cong, Y. (2013) Microbiota regulation of inflammatory bowel disease and colorectal cancer.  Semin Cancer Biol 23: 543-552. Crossref
  12. Arthur, J.C. and Jobin, C. (2013) The complex interplay between inflammation, the microbiota and colorectal cancer.  Gut Microbes 4: 253-258. Crossref
  13. Arthur, J.C., Gharaibeh, R.Z., Uronis, J.M., Perez-Chanona, E., Sha, W., Tomkovich S., Mühlbauer, M., Fodor, A.A. and Jobin, C. (2013) VSL 3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer.  Sci Rep 3: 2868. Crossref
  14. Hagland, H.R. and Soreide, K. (2015) Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways.  Cancer Lett 356: 273-280. Crossref
  15. Kverka, M. and Tlaskalova-Hogenova, H. (2012) Two faces of microbiota in inflammatory and autoimmune diseases: triggers and drugs.  APMIS 121: 403-421. Crossref
  16. Sartor, R.B. (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.Nat Clin Pract Gastroenterol Hepatol 3: 390-407. Crossref
  17. Lakshminarayanan, B., Stanton, C., O' Toole, P.W. and Ross, R.P. (2014) Compositional dynamics of the human intestinal microbiota with aging: implications for health. J Nutr Health Aging 18: 773-786. Crossref
  18. Kim, T.J., Kim, E.R., Chang, D.K., Kim, Y.H., Baek, S.Y., Kim, K. and Hong, S.N. (2017) Helicobacter pylori infection is an independent risk factor of early and advanced colorectal neoplasm.  Helicobacter 22: e12377. Crossref
  19. Gao, Z., Guo, B., Gao, R., Zhu, Q. and Qin, H. (2015) Microbiota disbiosis is associated with colorectal cancer.  Front Microbiol  6: 20. Crossref
  20. McCoy, A.N., Araújo-Pérez, F., Azcárate-Peril, A., Yeh, J.J., Sandler, R.S. and Keku T.O. (2013) Fusobacterium is associated with colorectal adenomas.  PLoS One 8: e53653. Crossref
  21. Balkwill, F.R., Capasso, M. and Hagemann, T. (2012) The tumor microenvironment at a glance.  J Cell Sci 125: 5591-5596. Crossref
  22. Wu, Y., Antony, S., Meitzler, J.L. and Doroshow, J.H. (2014) Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett 345: 164-173. Crossref
  23. Balkwill, F. and Mantovani, A. (2001) Inflammation and cancer: back to Virchow?  Lancet 357: 539-545. Crossref
  24. Das, V., Kalita, J. and Pal, M. (2017) Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.  Biomed Pharmacother 87: 8-19. Crossref
  25. Sebastian, S., Hernández, V., Myrelid, P., Kariv, R., Tsianos, E., Toruner, M., Marti-Gallostra, M., Spinelli, A., van der Meulen-de Jong, A.E., Yuksel, E.S., Gasche, C., Ardizzone, S. and Danese, S. (2014) Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).  J Crohns Colitis 8: 5-18. Crossref
  26. Abraham, C., Dulai, P.S., Vermeire, S. and Sandborn, W.J. (2017) Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology 152: 374-388. Crossref
  27. Hu, B., Elinav, E., Huber, S., Strowig, T., Hao, L., Hafemann, A., Jin, C., Wunderlich, C., Wunderlich, T., Eisenbarth, S.C. and Flavell, R.A. (2013) Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer.  Proc Natl Acad Sci U S A 110: 9862-9867. Crossref
  28. Rakoff-Nahoum, S. and Medzhitov, R. (2007) Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88.  Science 317: 124-127. Crossref
  29. Ramasamy, R., Yan, S.F. and Schmidt, A.M. (2012) Advanced glycation endproducts:  from  precursors to RAGE: round and round we go.  Amino Acids 42: 1151-1161. Crossref
  30. Ramasamy, R., Yan, S.F. and Schmidt, A.M. (2012) The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.  Vascul Pharmacol  57: 160-167. Crossref
  31. Lin, L. (2006) RAGE on the Toll Road? Cell Mol Immunol  3: 351-358.
  32. Akirav, E.M., Preston-Hurlburt, P., Garyu, J., Henegariu, O., Clynes, R., Schmidt, A.M. and Herold, K.C. (2012) RAGE expression in human T cells: a link between environmental factors and adaptive immune responses.  PLoS One 7: e34698. Crossref
  33. Todorova, J. and Pasheva, E. (2012) High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues.  Oncol Lett 3: 214-218. Crossref
  34. Taddei, M.L., Giannoni, E., Comito, G. and Chiarugi, P. (2013) Microenvironment and tumor cell plasticity: an easy way out.  Cancer Lett 341: 80-96. Crossref